Drug Class Detail

Drug Class EGFR Inhibitor 3rd gen

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
OBX1-012 EGFR Inhibitor 3rd gen 15 OBX1-012 is a third-generation inhibitor of mutant EGFR that specifically targets T790M, which may result in inhibition of cell proliferation and increased apoptotic activity (PMID: 29754184).
ZN-e4 EGFR Inhibitor 3rd gen 15 ZN-e4 is a third-generation EGFR inhibitor that inhibits activating mutations in EGFR, including those occurring at T790M (NCI Drug Dictionary)
AZ5104 AZ-5104 EGFR Inhibitor 3rd gen 15 AZ5104 is the active metabolite of Osimertinib, which inhibits wild-type and mutant EGFR and ERBB2 (HER2), potentially resulting in decreased tumor growth (PMID: 27439477, PMID: 28274957).
Rociletinib CO1686 EGFR Inhibitor 3rd gen 15 Rociletinib (CO-1686) is a third-generation EGFR TKI inhibitor and inhibits mutant forms of EGFR including T790M (PMID: 24410791).
Osimertinib Tagrisso AZD9291 EGFR Inhibitor 3rd gen 15 Tagrisso (osimertinib) is a third-generation EGFR inhibitor that selectively binds mutant forms of the EGF receptor, inhibiting downstream signaling and potentially reducing cell proliferation and growth in EGFR overexpressing tumors (NCI Drug Dictionary). Tagrisso (osimertinib) is FDA-approved for use in patients with non-small cell lung cancer harboring EGFR exon 19 deletions, L858R, or T790M (FDA.gov).
PF-06747775 Mavelertinib EGFR Inhibitor 3rd gen 15 Mavelertinib (PF-06747775) is a specific inhibitor of EGFR T790M, which causes cell death in EGFR T790M-positive tumor cells, while sparing wild-type EGFR (NCI Drug Dictionary).
WZ4002 EGFR Inhibitor 3rd gen 15 WZ4002 is a mutant-selective irreversible EGFR inhibitor that inhibits proliferation of tumor cells, including those harboring EGFR T790M (PMID: 20033049).
Alflutinib AST2818 EGFR Inhibitor 3rd gen 15 Alflutinib (AST2818) is a third generation EGFR inhibitor that targets both EGFR activating mutations and T790M, thus leads to tumor growth inhibition (J Thorac Oncol. Nov 2017, Vol 12, Issue 11, Suppl. 2, pS2138).
Olmutinib HM61713|BI 1482694|BI1482694 EGFR Inhibitor 3rd gen 15 Olmutinib (BI1482694, HM61713) is a third-generation EGFR inhibitor that inhibits activating mutations in EGFR, including those occurring with T790M, and spares wild-type EGFR, potentially resulting in decreased tumor growth (PMID: 25027951, PMID: 25521095, PMID: 30356705).
PF-06459988 EGFR Inhibitor 3rd gen 15 PF-06459988 is a third-generation irreversible EGFR inhibitor that is selective towards mutant EGFR, including T790M, and demonstrates little activity towards wild-type EGFR (PMID: 23456430).
CK-101 EGFR Inhibitor 3rd gen 15 CK-101 is a third generation EGFR inhibitor that preferentially binds to and inhibits mutant EGFR, particularly T790M, resulting in anti-tumor activity (NCI Drug Dictionary).
HS-10296 EGFR Inhibitor 3rd gen 15 HS-10296 is a third-generation small molecule inhibitor of EGFR activating mutations and EGFR T790M (PMID: 28149837).
Naquotinib ASP8273 EGFR Inhibitor 3rd gen 15 Naquotinib (ASP8273) is a third-generation EGFR inhibitor which binds mutant forms of EGFR, including T790M, thus preventing EGFR-mediated signaling and inducing cell death and growth inhibition of EGFR-overexpressing tumor cells (PMID: 29467275).
Avitinib maleate AC0010|AC0010MA EGFR Inhibitor 3rd gen 15 Avitinib maleate (AC0010) is a third generation EGFR inhibitor, which inhibits mutant forms of EGFR while sparing wild-type EGFR, resulting in increased tumor cell death (PMID: 27573423).
Nazartinib EGF816 EGFR Inhibitor 3rd gen 15 Nazartinib (EGF816) is a third generation EGFR inhibitor with selectivity towards mutant forms of EGFR, resulting in inhibition of tumor cell growth (PMID: 27433829).
Molecular Profile Protein Effect Treatment Approaches